Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CUTR's Cash-to-Debt is ranked higher than
98% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. NAS:CUTR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CUTR' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.63
NAS:CUTR's Equity-to-Asset is ranked higher than
55% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NAS:CUTR: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CUTR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.81 Max: 0.87
Current: 0.63
0.31
0.87
Interest Coverage No Debt
NAS:CUTR's Interest Coverage is ranked higher than
98% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. NAS:CUTR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CUTR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 11.28
Beneish M-Score: -2.22
WACC vs ROIC
3.22%
87.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.71
NAS:CUTR's Operating Margin % is ranked lower than
51% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. NAS:CUTR: 4.71 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CUTR' s Operating Margin % Range Over the Past 10 Years
Min: -20.83  Med: -7.94 Max: 9.39
Current: 4.71
-20.83
9.39
Net Margin % 5.07
NAS:CUTR's Net Margin % is ranked higher than
53% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. NAS:CUTR: 5.07 )
Ranked among companies with meaningful Net Margin % only.
NAS:CUTR' s Net Margin % Range Over the Past 10 Years
Min: -32.93  Med: -7.42 Max: 10.33
Current: 5.07
-32.93
10.33
ROE % 12.05
NAS:CUTR's ROE % is ranked higher than
61% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. NAS:CUTR: 12.05 )
Ranked among companies with meaningful ROE % only.
NAS:CUTR' s ROE % Range Over the Past 10 Years
Min: -16.6  Med: -6.99 Max: 12.05
Current: 12.05
-16.6
12.05
ROA % 7.85
NAS:CUTR's ROA % is ranked higher than
65% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. NAS:CUTR: 7.85 )
Ranked among companies with meaningful ROA % only.
NAS:CUTR' s ROA % Range Over the Past 10 Years
Min: -13.66  Med: -5.3 Max: 7.85
Current: 7.85
-13.66
7.85
ROC (Joel Greenblatt) % 83.86
NAS:CUTR's ROC (Joel Greenblatt) % is ranked higher than
82% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. NAS:CUTR: 83.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CUTR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1247.08  Med: -223.26 Max: 140.19
Current: 83.86
-1247.08
140.19
3-Year Revenue Growth Rate 18.40
NAS:CUTR's 3-Year Revenue Growth Rate is ranked higher than
82% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. NAS:CUTR: 18.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CUTR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 10.1 Max: 54.9
Current: 18.4
-18.1
54.9
GuruFocus has detected 3 Warning Signs with Cutera Inc $NAS:CUTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CUTR's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CUTR Guru Trades in Q3 2016

Jim Simons 1,045,400 sh (+1.91%)
Discovery Group I, LLC 97,194 sh (unchged)
Mario Gabelli 605,000 sh (unchged)
» More
Q4 2016

CUTR Guru Trades in Q4 2016

Discovery Group I, LLC 212,139 sh (+118.26%)
Jim Simons 1,063,260 sh (+1.71%)
Mario Gabelli 605,000 sh (unchged)
» More
Q1 2017

CUTR Guru Trades in Q1 2017

Jim Simons 1,205,400 sh (+13.37%)
Discovery Group I, LLC Sold Out
Mario Gabelli 556,000 sh (-8.10%)
» More
Q2 2017

CUTR Guru Trades in Q2 2017

Mario Gabelli 576,363 sh (+3.66%)
Jim Simons 1,214,500 sh (+0.75%)
» More
» Details

Insider Trades

Latest Guru Trades with CUTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Add 3.66%$19.2 - $26.55 $ 39.8583%576,363
Mario Gabelli 2017-03-31 Reduce -8.10%0.01%$17.45 - $21.9 $ 39.85102%556,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:IVC, NAS:GNMK, NAS:AXGN, NAS:TCMD, NAS:EXAC, NAS:ARAY, NAS:VRAY, NYSE:CRY, AMEX:CVRS, NAS:RTIX, ASX:RVA, OTCPK:BBLG, NAS:XENT, NAS:KTWO, NAS:FONR, ASX:OSP, NAS:OBLN, NAS:CGNT, NAS:ACRX, NAS:SPNE » details
Traded in other countries:TJ9.Germany,
Headquarter Location:USA
Cutera Inc is a medical device company. The Company is engaged in designing, development, manufacturing, marketing and servicing of laser and other energy based aesthetics systems for practitioners.

Cutera Inc was established in the San Francisco Bay Area in 1998. It is a medical device company, specializing in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners. It offers easy-to-use products based on four main platforms/systems Xeo, GenesisPlus, ExcelV, and truSculpt, each of which enables physicians and other qualified practitioners to perform safe and effective aesthetic procedures for their customers. The Xeo is a multi-application platform on which a customer can purchase hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, improving texture, reducing pore size, and treating fine lines and laxity. GenesisPlus platform, is a dedicated laser system for performing aesthetic skin procedures and for the temporary increase of clear nail in patients with onychomycosis, or toenail fungus. ExcelV is a high-performance, vascular platform designed specifically for the core-market of Dermatologists and Plastic Surgeons. This platform provides a combination of the 532 nm green laser with Cutera's award-winning 1064 nm Nd:YAG technology, to provide a single, compact and efficient system that treats the entire range of cosmetic vascular conditions, without the need for costly consumables. truSculpt is a high-powered radio frequency platform designed for the non-invasive body contouring market. This system is designed to treat all body areas and with its electrode design is able to achieve comfortable, uniform heating of the subcutaneous fat. In the U.S. its markets and sells its products mainly through a direct sales organization. International sales are generally made through a distributor network in over 60 countries. As of December 31, 2013, the Company had 30 issued U.S. patents and 11 pending U.S. patent applications. Its registered trademarks include Cutera, Acutip 500, CoolGlide, CoolGlide Excel, Limelight, myQ, Pearl, ProWave 770, ProWave LX, Solera, Titan, Xeo and truSculpt. The Company's products competes against laser and other energy-based products offered by public companies, such as Cynosure, Elen (in Italy), Lumenis, Syneron and Zeltiq, as well as private companies, including, Alma, Sciton, and several others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies.

Ratios

vs
industry
vs
history
PE Ratio 81.31
CUTR's PE Ratio is ranked lower than
87% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. CUTR: 81.31 )
Ranked among companies with meaningful PE Ratio only.
CUTR' s PE Ratio Range Over the Past 10 Years
Min: 14.53  Med: 54.9 Max: 343.09
Current: 81.31
14.53
343.09
Forward PE Ratio 48.31
CUTR's Forward PE Ratio is ranked lower than
86% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. CUTR: 48.31 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 81.31
CUTR's PE Ratio without NRI is ranked lower than
88% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. CUTR: 81.31 )
Ranked among companies with meaningful PE Ratio without NRI only.
CUTR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.53  Med: 54.9 Max: 343.09
Current: 81.31
14.53
343.09
Price-to-Owner-Earnings 106.55
CUTR's Price-to-Owner-Earnings is ranked lower than
99.99% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. CUTR: 106.55 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CUTR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.38  Med: 22.37 Max: 217.87
Current: 106.55
11.38
217.87
PB Ratio 9.26
CUTR's PB Ratio is ranked lower than
77% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. CUTR: 9.26 )
Ranked among companies with meaningful PB Ratio only.
CUTR' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.58 Max: 9.55
Current: 9.26
0.68
9.55
PS Ratio 4.29
CUTR's PS Ratio is ranked higher than
55% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. CUTR: 4.29 )
Ranked among companies with meaningful PS Ratio only.
CUTR' s PS Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.94 Max: 5.61
Current: 4.29
0.93
5.61
Price-to-Free-Cash-Flow 63.26
CUTR's Price-to-Free-Cash-Flow is ranked lower than
97% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. CUTR: 63.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CUTR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.78  Med: 53.85 Max: 1266
Current: 63.26
9.78
1266
Price-to-Operating-Cash-Flow 59.31
CUTR's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. CUTR: 59.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CUTR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.28  Med: 42.62 Max: 431.11
Current: 59.31
9.28
431.11
EV-to-EBIT 80.14
CUTR's EV-to-EBIT is ranked lower than
94% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. CUTR: 80.14 )
Ranked among companies with meaningful EV-to-EBIT only.
CUTR' s EV-to-EBIT Range Over the Past 10 Years
Min: -3233.4  Med: -3.05 Max: 695.7
Current: 80.14
-3233.4
695.7
EV-to-EBITDA 69.24
CUTR's EV-to-EBITDA is ranked lower than
94% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. CUTR: 69.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
CUTR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -503.2  Med: -2.95 Max: 172.5
Current: 69.24
-503.2
172.5
EV-to-Revenue 3.75
CUTR's EV-to-Revenue is ranked higher than
63% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. CUTR: 3.75 )
Ranked among companies with meaningful EV-to-Revenue only.
CUTR' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.2  Med: 0.8 Max: 6.3
Current: 3.75
-0.2
6.3
Current Ratio 2.83
CUTR's Current Ratio is ranked higher than
61% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. CUTR: 2.83 )
Ranked among companies with meaningful Current Ratio only.
CUTR' s Current Ratio Range Over the Past 10 Years
Min: 2.5  Med: 6.46 Max: 9.09
Current: 2.83
2.5
9.09
Quick Ratio 2.31
CUTR's Quick Ratio is ranked higher than
62% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. CUTR: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
CUTR' s Quick Ratio Range Over the Past 10 Years
Min: 2.21  Med: 5.97 Max: 8.66
Current: 2.31
2.21
8.66
Days Inventory 99.76
CUTR's Days Inventory is ranked higher than
64% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. CUTR: 99.76 )
Ranked among companies with meaningful Days Inventory only.
CUTR' s Days Inventory Range Over the Past 10 Years
Min: 66.49  Med: 104.48 Max: 137.01
Current: 99.76
66.49
137.01
Days Sales Outstanding 49.61
CUTR's Days Sales Outstanding is ranked higher than
76% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. CUTR: 49.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
CUTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.62  Med: 40.06 Max: 52.02
Current: 49.61
22.62
52.02
Days Payable 27.19
CUTR's Days Payable is ranked lower than
88% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. CUTR: 27.19 )
Ranked among companies with meaningful Days Payable only.
CUTR' s Days Payable Range Over the Past 10 Years
Min: 17.66  Med: 20.42 Max: 36.15
Current: 27.19
17.66
36.15

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.40
CUTR's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. CUTR: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CUTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -2.45 Max: 3
Current: 0.4
-13.6
3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 30.42
CUTR's Price-to-Net-Cash is ranked lower than
55% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 15.73 vs. CUTR: 30.42 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CUTR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.2  Med: 2.65 Max: 31.34
Current: 30.42
1.2
31.34
Price-to-Net-Current-Asset-Value 9.91
CUTR's Price-to-Net-Current-Asset-Value is ranked higher than
52% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 6.83 vs. CUTR: 9.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CUTR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.91  Med: 2.02 Max: 23.73
Current: 9.91
0.91
23.73
Price-to-Tangible-Book 9.47
CUTR's Price-to-Tangible-Book is ranked lower than
64% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. CUTR: 9.47 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CUTR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.77  Med: 1.93 Max: 20.68
Current: 9.47
0.77
20.68
Price-to-Intrinsic-Value-Projected-FCF 15.69
CUTR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
96% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. CUTR: 15.69 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CUTR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.42 Max: 1308
Current: 15.69
0.45
1308
Price-to-Median-PS-Value 2.22
CUTR's Price-to-Median-PS-Value is ranked lower than
74% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. CUTR: 2.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CUTR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.09 Max: 2.72
Current: 2.22
0.56
2.72
Price-to-Graham-Number 5.85
CUTR's Price-to-Graham-Number is ranked lower than
80% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. CUTR: 5.85 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CUTR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.93  Med: 2.04 Max: 7.76
Current: 5.85
0.93
7.76
Earnings Yield (Greenblatt) % 1.25
CUTR's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. CUTR: 1.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CUTR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -224.8  Med: -8 Max: 795.7
Current: 1.25
-224.8
795.7

More Statistics

Revenue (TTM) (Mil) $133.84
EPS (TTM) $ 0.49
Beta0.17
Short Percentage of Float2.55%
52-Week Range $11.50 - 41.15
Shares Outstanding (Mil)14.01

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 146 169 199 228
EPS ($) 0.52 0.83 1.20 1.30
EPS without NRI ($) 0.52 0.83 1.20 1.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
43.60%
Dividends per Share ($)
» More Articles for CUTR

Headlines

Articles On GuruFocus.com
Cutera to Present at the Sidoti & Company Fall 2017 Convention Sep 07 2017 
Cutera Strengthens Leadership Team with Two Key Executive Appointments Aug 21 2017 
Cutera Announces Retirement of Jerry P. Widman as Member of the Board of Directors Aug 18 2017 
Cutera, Inc. to Announce Results for the Second Quarter Ended June 30, 2017 Jul 20 2017 
Cutera Announces Engagement of Sandy Gardiner as Consultant CFO Jul 12 2017 
Cutera to Host Analyst & Investor Day on June 14, 2017 Jun 08 2017 
Cutera Names Darren W. Alch, Vice President, General Counsel and Secretary Jun 05 2017 
CUTERA Launches truSculpt® 3D … A New Dimension in Body Sculpting May 16 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cutera, Inc. for Potential Breache May 02 2017 
Cutera, Inc. to Announce Results for the First Quarter Ended March 31, 2017 Apr 25 2017 

More From Other Websites
Have Investors Already Priced In Cutera Inc’s (CUTR) Growth? Sep 21 2017
[$$] Cutera Set to Face Tougher Comps Sep 18 2017
ETFs with exposure to Cutera, Inc. : September 14, 2017 Sep 14 2017
Cutera, Inc. :CUTR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Sep 13 2017
Cutera to Present at the Sidoti & Company Fall 2017 Convention Sep 07 2017
Is Cutera an Incredible Momentum Stock? 3 Reasons Why CUTR Will Be Tough to Beat Sep 06 2017
Is Cutera (CUTR) a Great Growth Stock? Aug 25 2017
Cutera Strengthens Leadership Team with Two Key Executive Appointments Aug 21 2017
Cutera Announces Retirement of Jerry P. Widman as Member of the Board of Directors Aug 18 2017
Edited Transcript of CUTR earnings conference call or presentation 7-Aug-17 8:30pm GMT Aug 11 2017
Cutera, Inc.: Leads amongst peers with strong fundamentals Aug 09 2017
Cutera posts 2Q profit Aug 07 2017
Cutera Reports Second Quarter 2017 Financial Performance, Increases Revenue and EPS Guidance and... Aug 07 2017
Investor Network: Cutera, Inc. to Host Earnings Call Aug 07 2017
Cutera, Inc. to Announce Results for the Second Quarter Ended June 30, 2017 Jul 20 2017
Cutera Announces Engagement of Sandy Gardiner as Consultant CFO Jul 12 2017
New Analyst Coverage Make These 5 Stocks Worth a Bet Jul 03 2017
ETFs with exposure to Cutera, Inc. : June 2, 2017 Jun 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}